Sonnet BioTherapeutics Holdings Overview

Sonnet BioTherapeutics Holdings Research & Development

Research & Development expenses for SONN.

Quarterly R&D Expenses

$2.16M

↑ 80.06% YoY

As of Sep 30, 2025

Annual R&D Expenses (TTM)

$8.36M

↑ 47.21% YoY

Trailing 12 months ending Sep 30, 2025

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin